

## **EU Malaria Fund: DMG to receive financing to develop Fos-Clin-Art - a triple combination therapy for Plasmodium falciparum malaria**

Berlin / Malta on June 1, 2021 - Today DMG Deutsche Malaria GmbH concluded a contract with the EU Malaria Fund (EUMF) to receive €2.7 million for the development of DMG's antimalarial triple combination therapy. The therapy consists of three known drugs: fosmidomycin, clindamycin, and artesunate (Fos-Clin-Art).

DMG is a Hamburg-based company, founded in 2003 to fight malaria. DMG together with Prof. Peter Kremsner's group at the University of Tübingen is developing this new combination therapy for Plasmodium falciparum malaria. The triple combination Fos-Clin-Art aims at improving the outcome of both the severe and life-threatening Plasmodium falciparum malaria and of concomitant bacteraemia. Together, fosmidomycin and clindamycin cover the full spectrum of gram-negative and gram-positive bacteria, and also possess excellent intrinsic antimalarial activity additive to artesunate. Since all three substances have a short half-life, the triple combination is expected to ameliorate and shorten the duration of the needed treatment. The EUMF funding supports DMG's efforts to conduct the clinical development of Fos-Clin-Art with an overall participant number of more than 5.000 patients in Africa, especially children with severe malaria.

The EUMF is a public-private partnership between the European Union, international organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. The EU Malaria Fund is managed by Investitionsbank Berlin (IBB Group), with public benefit financing provided, among others, through and by the European Investment Bank (EIB). The EU Malaria Fund has been initiated by KENUP Foundation.

Dr. David Hutchinson, Managing Director of DMG, said: "As a recipient, DMG acknowledges the major contribution of the EUMF in facilitating the financing of projects of public health significance where funding is not ordinarily available. This initiative endorses the Company's objective to develop novel and improved therapies for malaria which are both safe and affordable for vulnerable populations at greatest risk from the disease. DMG expresses its sincere gratitude for the financial support it receives from the EUMF and applauds the establishment of this funding initiative."

Holm Keller, Co-Managing Director of EUMF and Chairman of KENUP Foundation said: "We are very excited about this investment and hope it can contribute by bringing this much needed malaria therapeutic into the clinic".

More information can be found at <https://www.controlmalaria.eu/Fos-Clin-Art> .  
Press Contact: Nadine Castillo, [castillo@kenup.eu](mailto:castillo@kenup.eu) , phone +356 7986-0103